Patents by Inventor Claudia Ferrara Koller
Claudia Ferrara Koller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12215152Abstract: Herein is reported an antibody that specifically hinds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.Type: GrantFiled: January 19, 2022Date of Patent: February 4, 2025Assignee: Hoffmann-La Roche Inc.Inventors: Claudia Ferrara Koller, Guy Georges, Alexander Haas, Hubert Kettenberger, Ekkehard Moessner, Tilman Schlothauer, Michael Molhoj, Laurent Lariviere
-
Patent number: 12202870Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.Type: GrantFiled: November 18, 2021Date of Patent: January 21, 2025Assignee: Hoffmann-La Roche Inc.Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
-
Publication number: 20240301079Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: ApplicationFiled: December 14, 2023Publication date: September 12, 2024Applicant: Roche GlycArt AGInventors: Pablo UMAÑA, Peter BRÚNKER, Claudia FERRARA KOLLER, Tobias SUTER, Ursula PÚNTENER, Ekkehard MÓSSNER
-
Patent number: 12065478Abstract: The invention relates to Her2 targeting 4-1BB agonists, in particular 4-1BBL trimer-containing antigen binding molecules comprising at least one antigen binding domain capable of specific binding to Her2 and their use in the treatment of cancer as well as their use in combination with T-cell activating anti-CD3 bispecific antibodies.Type: GrantFiled: October 9, 2020Date of Patent: August 20, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Claudia Ferrara Koller, Teemu Tapani Junttila, Christian Klein, Pablo Umana, Christina Claus
-
Publication number: 20240043535Abstract: The present invention generally relates to novel immune activating Fc domain binding molecules for activation of immune cells and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: December 16, 2022Publication date: February 8, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Maria Amann, Alejandro Carpy Gutierrez Cirlos, Christina Claus, Laura Codarri Deak, Diana Darowski, Tanja Fauti, Claudia Ferrara Koller, Anne Freimoser-Grundschober, Sylvia Herter, Thomas Hofer, Christian Klein, Laura Lauener, Stephane Leclair, Ekkehard Moessner, Christiane Neumann, Pablo Umaña, Ali Bransi, Marlena Surówka
-
Publication number: 20230357397Abstract: The present invention relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies and/or agents blocking PD-L1/PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.Type: ApplicationFiled: February 9, 2023Publication date: November 9, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Marina BACAC, Christina CLAUS, Claudia FERRARA KOLLER, Christian KLEIN, Sabine LANG, Viktor LEVITSKI, Pablo UMAÑA
-
Publication number: 20230312710Abstract: The present invention relates to antibodies against human CD19 (anti-human CD19 antibodies), methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.Type: ApplicationFiled: November 3, 2022Publication date: October 5, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Thomas Hofer, Claudia Ferrara Koller, Ekkehard Moessner, Mi He
-
Patent number: 11718680Abstract: The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.Type: GrantFiled: March 16, 2020Date of Patent: August 8, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Marina Bacac, Claudia Ferrara Koller, Christian Klein, Mario Perro, Johannes Sam, Pablo Umaña, Wei Xu
-
Publication number: 20230212303Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: ApplicationFiled: August 24, 2022Publication date: July 6, 2023Applicant: Roche GlycArt AGInventors: Pablo UMAÑA, Peter Brúnker, Claudia Ferrara Koller, Tobias Suter, Ursula Púntener, Ekkehard Móssner
-
Publication number: 20230123178Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules having at least one moiety capable of specific binding to PD1 and a first and a second polypeptide that are linked to each other by a disulfide bond, the first polypeptide having two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and the second polypeptide having a single ectodomain of the same TNF ligand family member or a fragment thereof.Type: ApplicationFiled: January 28, 2022Publication date: April 20, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Claudia Ferrara Koller, Christina Claus, Christian Klein, Stefan Seeber, Maria Amann, Sandra Grau-Richards, Peter Bruenker, Pablo Umana, Viktor Levitski, Ekkehard Moessner
-
Publication number: 20230086210Abstract: The invention relates to 4-1BBL trimer-containing antigen binding molecules comprising at least one antigen binding domain capable of specific binding to PD-L1 and their use in the treatment of cancer.Type: ApplicationFiled: July 8, 2022Publication date: March 23, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Christina CLAUS, Claudia FERRARA KOLLER, Christian Klein, Pablo Umana
-
Publication number: 20230045262Abstract: The invention relates to new bispecific antigen binding molecules, comprising at least one antigen binding domain capable of specific binding to 4-1BB, at least one moiety capable of specific binding to a target cell antigen, and a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: August 15, 2022Publication date: February 9, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Claudia FERRARA KOLLER, Christina CLAUS, Christian KLEIN, Pablo UMAÑA, Wei XU
-
Patent number: 11447558Abstract: The invention relates to new bispecific antigen binding molecules, comprising at least one antigen binding domain capable of specific binding to 4-1BB, at least one moiety capable of specific binding to a target cell antigen, and a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.Type: GrantFiled: June 19, 2019Date of Patent: September 20, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Claudia Ferrara Koller, Christina Claus, Christian Klein, Pablo Umaña, Wei Xu
-
Publication number: 20220267395Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: November 18, 2021Publication date: August 25, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
-
Publication number: 20220267464Abstract: The invention relates to new humanized CEA antibodies and to CEA targeting 4-1BBL trimer-containing antigen binding molecules comprising these CEA antibodies as well as their use in the treatment of cancer.Type: ApplicationFiled: December 17, 2021Publication date: August 25, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Claudia Ferrara Koller, Thomas Hofer, Christian Klein, Ekkehard Moessner, Christina Claus, Ralf Hosse, Bianca Scherer, Pablo Umana
-
Publication number: 20220259327Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.Type: ApplicationFiled: January 21, 2022Publication date: August 18, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
-
Publication number: 20220259326Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.Type: ApplicationFiled: January 21, 2022Publication date: August 18, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
-
Publication number: 20220204616Abstract: Herein is reported an antibody that specifically hinds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.Type: ApplicationFiled: January 19, 2022Publication date: June 30, 2022Inventors: Claudia Ferrara Koller, Guy Georges, Alexander Haas, Hubert Kettenberger, Ekkehard Moessner, Tilman Schlothauer, Michael Molhoj, Laurent Lariviere
-
Publication number: 20220162295Abstract: Herein is reported a method for producing an antibody-multimer-fusion polypeptide comprising (a) an antibody heavy chain and an antibody light chain, and (b) a first fusion polypeptide comprising in N- to C-terminal direction a first part of a non-antibody multimeric polypeptide, an antibody heavy chain CH1 domain or an antibody light chain constant domain, an antibody hinge region, an antibody heavy chain CH2 domain and an antibody heavy chain CH3 domain, and a second fusion polypeptide comprising in N- to C-terminal direction the second part of the non-antibody multimeric polypeptide and an antibody light chain constant domain if the first polypeptide comprises an antibody heavy chain CH1 domain or an antibody heavy chain CH1 domain if the first polypeptide comprises an antibody light chain constant domain, wherein (i) the antibody heavy chain of (a) and the first fusion polypeptide of (b), (ii) the antibody heavy chain of (a) and the antibody light chain of (a), and (iii) the first fusion polypeptide of (Type: ApplicationFiled: July 22, 2021Publication date: May 26, 2022Applicants: Hoffmann-La Roche Inc., Genentech, Inc.Inventors: Styliani Tournaviti, Shan-Hua Chung, Harald Duerr, Claudia Ferrara Koller, Amy Shen, Shahram Misaghi, Shuet Ming Yip
-
Patent number: 11306154Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.Type: GrantFiled: July 25, 2019Date of Patent: April 19, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana